AI Applications in Cancer Stem Cell Immunotherapy: A Comprehensive Review
A scientific review highlights AI's role in guiding precision immunogenetics for cancer stem cell-targeted cellular therapies, emphasizing its current potential and challenges.

AI in Healthcare and Biotechnology
Part 1 of 1
Table of Contents
A detailed review published in the Journal of the Egyptian National Cancer Institute evaluates artificial intelligence (AI) applications in cancer stem cell (CSC) immunotherapy. The authors examine CSCs’ biological features—such as plasticity, immune evasion, and therapeutic resistance—that hinder eradication in solid tumors.
The review discusses how AI and machine learning integrate multi-omics and clinical data to assist antigen discovery, optimize chimeric antigen receptor (CAR) designs, and stratify patients. While CAR-T cell therapies have advanced hematological cancer treatment, AI-driven approaches aim to overcome antigen heterogeneity and immune escape to improve CSC targeting.
The authors describe various engineered cellular platforms, including CAR-T, CAR-NK, CAR-macrophages, CAR-iNKT, and others, each with unique advantages and limitations. Challenges such as immune exhaustion, tumor microenvironment immunosuppression, and metabolic barriers are also highlighted.
Despite promising computational models, the review emphasizes that AI applications remain largely exploratory, with evidence mainly from retrospective data and theoretical frameworks rather than prospective clinical trials. It calls for standardized datasets, explainable AI models, longitudinal profiling, and rigorous clinical validation to translate AI-guided therapies into safe and effective treatments.
This comprehensive assessment underscores AI’s potential to guide precision immunogenetics for CSC-targeted CAR immunotherapy while recognizing the need for further experimental and clinical validation.
Source: Bioengineer.org.


